Type 1 Diabetes Driven by Residual Recipient T Cells After Hematopoietic Cell Transplantation: A Case Report.

Diabetes CareSep 1, 2026
Case ReportHematologyEndocrinologyOpen access

Martin A Thelin, Soohee Cho, Aïsha Callebaut et al.

✦ AI-curated · Sources linked

Case in brief

A patient developed type 1 diabetes following haploidentical hematopoietic cell transplantation. Analysis revealed an expanded population of islet-specific CD4+ T cells in the recipient, predominantly restricted by recipient-specific HLA alleles, indicating that the diabetes was driven by residual host T cells rather than donor autoimmunity. The condition persisted despite extensive immunotherapy.

Diagnostic / clinical pearl

Clinicians should consider the possibility of residual recipient T cells as a cause of posttransplant type 1 diabetes, particularly in cases with significant donor chimerism.

Why it matters

This case highlights the potential for established islet autoimmunity to persist despite myeloablative conditioning and immunotherapy, emphasizing the complexity of posttransplant diabetes management.

Source

PubMed · PMID 42411999Free full text on PubMed Central

Published in Diabetes Care. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.